Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine

Chronic Migraine Clinical Trial

Official title:

An Open Post-marketing Clinical Follow-up Investigation to Follow Long-term Performance and Safety of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05843721
• Other study ID #: PM010
• Status: Recruiting
• Phase: N/A
• Start date: November 8, 2023
• Est. completion date: January 15, 2025

Study information

• Verified date: May 2024
• Source: Chordate Medical
• Contact: Peter J Goadsby, Prof,MD,PhD
• Phone: +44-20-3299 3106
• Email: peter.goadsby[@]kcl.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An non controlled, long term, multi center investigation

Description:

Subjects who provided written informed consent and are eligible for the study will be asked to complete a daily diary for 4 weeks during the screening period. In the diary the subjects will record headache and migraine days, any changes in their health, and concomitant medications they may be using. The data collected in the diary during this screening period will be used as Baseline for the performance assessments.

A non-controlled, long term, multi-center investigation for symptom improvement in subjects suffering headache and migraine attacks.

During the run-in (baseline) period and through the whole study the subjects will continue using their existing prescribed or over the counter (OTC) treatments.

Following the run-in period (4 weeks) the subjects will be treated six times within a period that is approximately 6 weeks. The first treatment will be given the first day after the run-in period.

During 12-month follow-up period (from the time of the first treatment), subjects will be treated when needed but a maximum of 14 treatments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: January 15, 2025
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

INCLUSION AND EXCLUSION CRITERIA:

Inclusion Criteria

1. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form;

2. Male or female aged between 18 and 70 years (inclusive) at the time of providing informed consent;

3. Diagnosed with chronic migraine with or without aura (=15 headache days per month including at least 8 migraine days for more than 3 months before screening) according to the International Headache Society classification (International Classification of Headache Disorders III);

4. Migraine onset before the age of 65 years;

5. Reported history of migraine for at least 1 year before screening;

6. Able and willing to maintain current prophylactic migraine medication regimen (if any) (no change in type, frequency or dose) from screening to at least the 6-month follow-up;

7. Women of childbearing potential must be willing to use highly effective contraceptive methods (failure rate <1% per year when used consistently and correctly) during the study.

Exclusion Criteria

1. Unable to distinguish between migraine headache and other headache types;

2. An ongoing upper respiratory infection, nasal tumors, or wounds in the nasal cavity.

3. Nasal cavity abnormalities that prevents catheter insertion.

4. A concomitant condition that could cause excessive nose bleeding or ongoing treatment with anticoagulant medication (except Aspirin and Clopidogrel).

5. A known allergy to polyurethane (polyurethane is used in the catheter balloon).

6. Systemic diseases with manifestations in the nose.

7. Previous treatment with radiation therapy to the nasal area.

8. Nasal surgery performed within the last six months.

9. Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation;

10. Pregnant and lactating women;

11. Participation in a clinical investigation within 3 months of enrolment or planned participation at any time during this clinical investigation;

12. Previous participation in this study;

13. Employees of the study site or the sponsor directly involved with the conduct of the study, or immediate family members of any such individuals.

Only at baseline visit (day 0) If subject missed >4 days of eDiary entry, subject will be withdrawn.

Related Conditions & MeSH terms

• Chronic Migraine
• Migraine Disorders

Intervention

Device:
• KOS (Intranasal kinetic oscillation stimulation)
Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.

Locations

Country	Name	City	State
Germany	Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden UniversitätsSchmerzCentrum	Dresden
Germany	Universitätsklinikum Essen (AöR) Klinik für Neurologie Kopfschmerz- und Schwindelambulanz	Essen
Germany	Kopfschmerzzentrum Frankfurt	Frankfurt am main
Germany	Klinikum St. Georg Klinik für Neurologie	Leipzig
Germany	Universitätsklinikum Tübingen Klinik für Neurologie	Tübingen
Israel	Shaare Zedek Medical Center, Neurology Clinics,	Jerusalem
Italy	Università de L'Aquila Dipartimento di Scienze Cliniche applicate e Biotecnologie SSD Neurologia	L'Aquila
Italy	IRCCS Istituto Auxologico Italiano U.O. Neurologia - Centro Cefalee	Milano
Italy	Centro Regionale Diagnosi e Cura delle Cefalee IRCCS National Neurological Institute "C. Mondino" Foundation	Pavia
Italy	IRCCS San Raffaele Pisana Dipartimento di Scienze Neurologiche Motorie e Sensoriali Unità per la Cura e la Ricerca su Cefalee e Dolore	Roma
Italy	Policlinico Universitario Campus Bio-Medico di Roma UOC Neurologia	Roma
United Kingdom	Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital	Glasgow
United Kingdom	Hull Royal Infirmary, Hull University Teaching Hospital NHS Trust	Hull
United Kingdom	National Migraine Centre	London
United Kingdom	St. George's University Hospitals NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Chordate Medical

Countries where clinical trial is conducted

Germany,  Israel,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of intranasal kinetic oscillation stimulation using the Chordate System S220 on monthly headache days with moderate to severe intensity after approx 6 weeks of treatment.	Change in proportion of days with headache with moderate to severe intensity compared to the four week period starting the day after the third treatment Headache days are collected in electronic diary (eDiary)	Baseline to 6 weeks
Secondary	To evaluate the efficacy of treatment with KOS on monthly migraine days (regardless of intensity) Description: Migraine days are collected in an eDiary.	Migraine days is collected in an eDiary.	Baseline to 12 month
Secondary	To evaluate the incidence and severity of adverse events (AEs) and adverse device effects (ADEs) following treatment with the Chordate System S220.	All adverse events (AEs) and adverse device effects (ADEs) incidence and severity following treatment with KOS	Baseline to 12 month
Secondary	Number of patients who are responders	Responders are classified as responder (less migraine/headache days) or non-responder (same or worsening of migraine/headache days).; A responder is a patient who has decrease of headache/migraine days whilst a non responder had no or the same number of headache/migraine days	Baseline to 12 month
Secondary	Number of patients who decrease use of abortive medication	Intake of abortive medications are registered in eDiary and will be calculated on patient level	Baseline to 12 month
Secondary	Mean change in Headache Impact Test (HIT-6)	HIT-6 consist of 6 questions HIT-6 with scores from 6 to 13 where 13 is worst case per question so lower score is better outcome than high scores.	Baseline to 12 month
Secondary	Mean change in Subject global severity	Patient Global severity is a scale with four (4) scores, where normal (0) is the lowest and show no problems whilst severe (3) is the worst score 0. Normal; Mild; Moderate; Severe	Baseline to 12 month